drugset / Trial / NCT04901078
A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers
Phase 1
Completed
57 enrolled
Kinoxis Therapeutics Pty Ltd
National Institute on Drug Abuse (NIDA) · collab
RandomizedSequentialDouble-blindTreatment
Summary
The primary objectives of this study are to evaluate the safety and tolerability of KNX100 administered orally as a single and multiple ascending doses in healthy volunteers.
Timeline
- Start
- 2022-04-07
- Primary completion
- 2023-09-30
- Completion
- 2023-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KNX100 | Unknown | 25 mg | Oral |
| Subject | KNX100 | Unknown | 50 mg | Oral |